Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

203
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
203
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

446
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
446
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

407
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
407
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

332
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
332
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

553
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
553
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

639
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
639

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of Microvascular Decompression for Young-Onset Trigeminal Neuralgia.

Neurosurgery·2026
Same author

White matter microstructural alterations in episodic cluster headache outside attacks: a tract-based spatial statistics study.

The journal of headache and pain·2026
Same author

Quantitative Sensory Testing Identifies Altered Thermal and Pain Processing in Trigeminal Neuralgia.

European journal of neurology·2026
Same author

Topical capsaicin 8% differentially blocks activation of nociceptors by mechanical, heat, and electrical stimuli in human skin.

Pain·2026
Same author

Exceptional long attenuation of chemically evoked itch and axon reflex flare after topical 8% capsaicin.

The Journal of investigative dermatology·2026
Same author

Muscle Ultrasound in Inclusion Body Myositis: Integrating Qualitative and Quantitative Approaches With Clinical and MRI Findings.

Muscle & nerve·2026
Same journal

Advances in the Application of Brain-Computer Interface-Based Neurofeedback Training in the Rehabilitation of Patients with Major Depressive Disorder.

Neuropsychiatric disease and treatment·2026
Same journal

Second-Generation Long-Acting Injectable Antipsychotics: A Comprehensive Assessment of Effectiveness, Safety, and Cost.

Neuropsychiatric disease and treatment·2026
Same journal

Resting-State EEG Characteristics of Tardive Dyskinesia: Spectral and Network Connectivity Insights.

Neuropsychiatric disease and treatment·2026
Same journal

Efficacy of Adjunctive Lumateperone 42 mg on Anhedonia and Across a Broad Range of Depressive Symptoms in Major Depressive Disorder: Post Hoc Analysis of a Phase 3, Randomized, Placebo-Controlled Trial.

Neuropsychiatric disease and treatment·2026
Same journal

Modifying Neuropsychiatric and Motor Trajectories in Huntington's Disease Through an Integrated Neurobehavioral Clinic Model.

Neuropsychiatric disease and treatment·2026
Same journal

Mini-Review: Allicin as a Potential Neuroprotective Compound in Neurological Disorders.

Neuropsychiatric disease and treatment·2026
See all related articles

Related Experiment Video

Updated: Jul 15, 2025

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain
09:35

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain

Published on: May 10, 2017

18.9K

Considerations When Using Gabapentinoids to Treat Trigeminal Neuralgia: A Review.

Gianfranco De Stefano1, Giuseppe Di Pietro1, Andrea Truini1

  • 1Department of Human Neuroscience, Sapienza University, Rome, Italy.

Neuropsychiatric Disease and Treatment
|September 25, 2023
PubMed
Summary
This summary is machine-generated.

Gabapentin and other alpha2-delta ligands show promise for treating trigeminal neuralgia, especially when first-line drugs cause side effects or fail. Further research is needed due to low-quality evidence.

Keywords:
gabapentinpregabalintrigeminal neuralgia

More Related Videos

Microvascular Decompression: Salient Surgical Principles and Technical Nuances
10:35

Microvascular Decompression: Salient Surgical Principles and Technical Nuances

Published on: July 5, 2011

46.5K
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

48.2K

Related Experiment Videos

Last Updated: Jul 15, 2025

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain
09:35

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain

Published on: May 10, 2017

18.9K
Microvascular Decompression: Salient Surgical Principles and Technical Nuances
10:35

Microvascular Decompression: Salient Surgical Principles and Technical Nuances

Published on: July 5, 2011

46.5K
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

48.2K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Voltage-gated sodium channel blockers are first-line treatments for trigeminal neuralgia but cause side effects.
  • Their efficacy may decrease in patients with continuous pain, necessitating alternative treatments.

Purpose of the Study:

  • To review current evidence on gabapentin and other alpha2-delta ligands for trigeminal neuralgia.
  • To assess the efficacy and tolerability of these agents.

Main Methods:

  • Systematic search of PubMed, EMBASE, Cochrane Database, and ClinicalTrials.gov up to April 2023.
  • Inclusion and data extraction by two independent authors.
  • Analysis of seven controlled or open-label studies.

Main Results:

  • Gabapentin and pregabalin (alpha2-delta ligands) were assessed in the included studies.
  • Evidence quality is currently low.
  • These agents have a favorable tolerability profile.

Conclusions:

  • Alpha2-delta ligands are of interest for trigeminal neuralgia treatment, particularly for continuous pain.
  • Their favorable tolerability profile warrants further investigation in clinical trials.
  • Future research should focus on higher-quality studies to confirm efficacy.